Literature DB >> 12946705

Ionotropic and metabotropic glutamate receptor mediation of glucocorticoid-induced apoptosis in hippocampal cells and the neuroprotective role of synaptic N-methyl-D-aspartate receptors.

J Lu1, D Goula, N Sousa, O F X Almeida.   

Abstract

Glutamate receptors have been proposed to mediate the apoptotic actions of glucocorticoids in hippocampal cells. To further analyze the role of glutamate receptors in this process, we pretreated primary hippocampal cells from neonatal (postnatal day 4) rats with antagonists of ionotropic glutamate receptor (iGluR) and metabotropic glutamate receptor (mGluR) antagonists before exposure to the specific glucocorticoid receptor agonist dexamethasone (DEX) at a dose of 1 microM. Dizocilpine (MK801; a general N-methyl-D-aspartic acid [NMDA] receptor antagonist, NMDAR antagonist) and ifenprodil (a specific ligand of the NMDAR 2B subunit, NR2B), were used to block iGluR; (RS)-alpha-ethyl-4-carboxyphenylglycine (E4CPG) and (RS)-alpha-cyclopropyl-4-phosphonophenyl-glycine (CPPG) were employed as I/II (E4CPG) and II/III (CPPG) mGluR antagonists. Blockade of iGluR resulted in a significant attenuation of DEX-induced cell death; the finding that ifenprodil exerted a similar potency to MK801 demonstrates the involvement of NR2B receptors in glucocorticoid-induced cell death. Apoptosis accounted for a significant amount of the cell loss observed, as detected by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling histochemistry for the in situ labeling of DNA breaks; apoptotic cells were distinguished from necrosis on the basis of morphological criteria, including chromatin condensation, membrane blebbing and presence of apoptotic bodies. Treatment with E4CPG and CPPG completely abolished the apoptotic response to DEX, thus showing the additional contribution of mGluR to the phenomenon. Further, dose-response studies with NMDA revealed that whereas high (10 microM) doses of NMDA themselves elicit cytotoxic responses, low (1-5 microM) concentrations of NMDA can effectively oppose DEX-induced cell death. Interestingly, the neuroprotective actions of low dose NMDA stimulation were abolished when either synaptic or extrasynaptic NMDA receptors were blocked with MK801 in combination with the GABA receptor antagonist bicuculline (synaptic) or ifenprodil (extrasynaptic). In summary, the present data show that both iGluR and mGluR mediate the neurotoxic effects of glucocorticoids on hippocampal cells and that pre-treatment with low doses of NMDA, by acting on synaptic and extrasynaptic receptors, render hippocampal cells less vulnerable to glucocorticoid insults.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946705     DOI: 10.1016/s0306-4522(03)00421-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  16 in total

Review 1.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

2.  Neuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neurons.

Authors:  M-Y Zhu; W-P Wang; G Bissette
Journal:  Neuroscience       Date:  2006-06-13       Impact factor: 3.590

3.  Recombinant hexahistidine arginine decarboxylase (hisADC) induced endogenous agmatine synthesis during stress.

Authors:  Sung-Ung Moon; Ki-Hyo Kwon; Jae-Hwan Kim; Kiran Kumar Bokara; Kyung Ah Park; Won Taek Lee; Jong-Eun Lee
Journal:  Mol Cell Biochem       Date:  2010-08-21       Impact factor: 3.396

4.  Central glucocorticoid receptors modulate the expression and function of spinal NMDA receptors after peripheral nerve injury.

Authors:  Shuxing Wang; Grewo Lim; Qing Zeng; Backil Sung; Liling Yang; Jianren Mao
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

Review 5.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

6.  Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.

Authors:  Brett D Dufour; Jodi L McBride
Journal:  Neurobiol Dis       Date:  2018-10-05       Impact factor: 5.996

Review 7.  Methylene blue and its analogues as antidepressant compounds.

Authors:  Anzelle Delport; Brian H Harvey; Anél Petzer; Jacobus P Petzer
Journal:  Metab Brain Dis       Date:  2017-07-31       Impact factor: 3.584

8.  Synaptic neurotransmission depression in ventral tegmental dopamine neurons and cannabinoid-associated addictive learning.

Authors:  Zhiqiang Liu; Jing Han; Lintao Jia; Jean-Christian Maillet; Guang Bai; Lin Xu; Zhengping Jia; Qiaohua Zheng; Wandong Zhang; Robert Monette; Zul Merali; Zhou Zhu; Wei Wang; Wei Ren; Xia Zhang
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

9.  Glucocorticoid regulation of astrocytic fate and function.

Authors:  Shuang Yu; Silei Yang; Florian Holsboer; Nuno Sousa; Osborne F X Almeida
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

10.  Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword.

Authors:  Amanda L Gruver-Yates; John A Cidlowski
Journal:  Cells       Date:  2013-03-26       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.